Kennedy, M J <br/><br/>
Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 1995 
 - 1136-43 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1995.13.5.1136  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anemia, Aplastic--chemically induced<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Breast Neoplasms--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Drug Resistance<br/>Female<br/>Gastrointestinal Diseases--chemically induced<br/>Humans<br/>Length of Stay<br/>Lymphatic Metastasis<br/>Middle Aged<br/>Mouth Mucosa--drug effects<br/>Neutropenia--chemically induced<br/>Novobiocin--administration & dosage<br/>Prospective Studies<br/>Stomatitis--chemically induced<br/>Thiotepa--administration & dosage